- SID Score
- 6.9/10
- Fair value
- $277.51
- Generated
- Oct 10, 2026
- Model
- claude-haiku-4-5-20251001
Johnson & Johnson is trading at $261.44 with a market capitalization of $505.8 billion, positioning it as a dominant player in the healthcare sector. The stock presents a mixed investment picture with a fair value estimate of $277.51 suggesting 8.4% upside potential, though this conflicts with the analyst consensus average price target of $207.08, indicating significant analytical uncertainty. The SID Score of 6.9/10 reflects moderate investment quality, while recent earnings performance has been solid with consistent beats or near-meets of estimates across the past four quarters. The current valuation at a P/E ratio of 20.3x reflects premium pricing typical of established healthcare companies with defensive characteristics.
JNJ demonstrates consistent profitability with recent quarterly EPS results exceeding expectations in three of the last four quarters, including a notable beat of $2.90 actual versus $2.85 estimated in Q2 2026. However, the Profitability factor grade of C suggests concerns about earnings quality or margin sustainability despite the absolute performance metrics. The Value grade of D indicates the stock is trading at a premium to intrinsic value based on traditional valuation metrics, while the Growth grade of B reflects expectations for moderate business expansion. The low dividend yield of 0.02% is unusually depressed for a healthcare company of JNJ's stature, suggesting either recent price appreciation or dividend policy changes that warrant further investigation.
The RSI(14) reading of 27.6 indicates the stock is approaching oversold territory, traditionally a signal that selling pressure may be exhausted and a bounce could be imminent. Price momentum is positive as JNJ trades above both its 50-day moving average ($265.22) and 200-day moving average ($246.62), establishing a constructive technical setup with approximately 15 points of support at the 50-day level. The stock's current position of $261.44 sits between these key moving averages with modest upside room to recent resistance, suggesting intermediate-term consolidation rather than strong directional conviction. The technical profile supports a cautious bullish stance, particularly if the RSI oversold condition triggers a mean-reversion rally.
Analyst & Insider Sentiment
Insider activity presents a notably conflicting picture with significant net selling by Timothy Schmid (33,597 shares sold on September 2) offset by smaller purchases by three executives (Eugene Woods, Daniel Pinto, and Marillyn Hewson purchasing 136, 113, and 181 shares respectively on September 8). The concentrated selling by Schmid appears opportunistic given the stock's proximity to recent highs, while the subsequent insider purchases by other executives could represent confidence at lower levels or routine portfolio management. The analyst consensus rating of "Buy" contradicts the substantially lower average price target of $207.08, suggesting analysts view the stock as overvalued despite positive sentiment, creating an unusual disconnect. This mixed insider and analyst picture warrants cautious interpretation and suggests waiting for clearer directional signals.
The significant discrepancy between the fair value estimate of $277.51 and the analyst average price target of $207.08 represents a material valuation risk of approximately 26% downside, indicating substantial disagreement about appropriate valuation levels within the investment community. The D-grade in Value combined with a C-grade in Profitability suggests potential concerns about earnings sustainability, margin pressure, or competitive dynamics that could pressure future multiples and earnings power. Momentum factor grade of C combined with the oversold RSI (27.6) creates timing risk—while oversold conditions can precede rallies, they may also indicate fundamental deterioration that warrants further investigation before accumulation. The unavailability of recent annual financial data limits the ability to perform comprehensive analysis on balance sheet strength, cash flow generation, and operational trends that are critical for healthcare sector investors.
Johnson & Johnson presents a defensive healthcare holding with solid recent earnings execution and technical signs of oversold conditions, making it suitable for risk-averse investors seeking portfolio stability rather than growth acceleration. The fair value estimate of $277.51 implies modest upside of 8.4%, though this is substantially undermined by the conflicting analyst price target, creating uncertainty about appropriate entry points and warranting additional due diligence before significant capital allocation. Investors should monitor the next earnings report to verify whether the recent EPS beat streak continues and whether management commentary addresses profitability and growth concerns reflected in the factor grades. Optimal strategy would involve accumulating positions on any weakness toward the 50-day moving average at $265.22 or waiting for clarity on the valuation discrepancy, while avoiding aggressive positions given the D-grade value assessment and conflicting price targets.
